Abstract
Abstract Background Association of serious bacterial infections (SBI) and preceding respiratory viral illness (RVI) has been described. Social distancing, (masking and lockdowns), in response to pandemic resulted in > 95% decrease in RVI, specifically influenza (Flu). Invasive Streptococcus pneumoniae (iSpneumo) and Streptococcus pyogenes (iGABHS) have substantial morbidity and mortality. Decrease in culture (Cx) proven iSpneumo during COVID has been reported. We used PCR in empyema fluid for enhanced SBI microbiologic diagnosis. Here, we evaluate Cx/PCR diagnosed community acquired SBI (CA-SBI) in children and relationship with Flu burden and social distancing. Methods Data from surveillance of bacteremia and CA-empyema (Cx and PCR) at our institution was used to identify CA-SBI cases in children 3 months – < 18 years. Spinal fluid Cxs were reviewed to identify meningitis cases. We used data from the Orange County Health Care Agency for detection of countywide Flu trends. We normalized yearly CA-SBI cases per 10,000 discharges, grouped them into before COVID (BC) (7/1/2017 – 12/31/19) and after covid (AC) (1/1/2020 – 6/30/2022), and compared to countywide Flu cases 7/1/2017 – 6/30/2022. Results We identified 361 CA-SBIs. S aureus (95; 26.3%) and E coli (65, 18%) were most common overall (Fig 1) and per cohort (BC 45; 25.7% and 25; 14.3% / AC 50; 26.9% and 40; 21.5%) respectively (Fig 2); 35.7% and 12.9% of iSpneumo and iGABHS respectively were identified by PCR only. Both decreased during COVID (iSpneumo BC 40; 22.9% to AC 16; 8.6% and iGABHS BC 24; 13.7% to AC 7; 3.8%). iSpneumo and iGABHS mortality was 3.6% and 12.9% respectively. There were no iSpneumo (5/2020 – 10/2021) or iGABHS 12/2020 – 11/2021) cases or deaths when Flu was not circulating. Conclusion iSpneumo and iGABHS cases decreased during social distancing, which included mandatory masking. No cases or deaths occurred when Flu was not circulating supporting association with Flu. Decrease in iSpneumo by routine pediatric vaccination has limitations due to differential protection by serotype and serotype replacement. Seasonal masking should be evaluated to decrease CA-SBI associated pediatric morbidity and mortality due to iSpneumo and iGABHS, further Flu vaccine development is needed. Disclosures Antonio C. Arrieta, MD, FIDSA, FPIDS, Astellas Pharma Global Development, Inc.: Advisor/Consultant|Astellas Pharma Global Development, Inc.: Grant/Research Support|Astellas Pharma Global Development, Inc.: Honoraria|Cumberland Pharmaceutical: Grant/Research Support|IDbyDNA: Advisor/Consultant|IDbyDNA: Grant/Research Support|Melinta: Grant/Research Support|Merck: Advisor/Consultant|Merck: Grant/Research Support|Nabriva: Grant/Research Support|Paratek Pharmaceuticals: Grant/Research Support|Pfizer, Inc: Advisor/Consultant|Pfizer, Inc: Grant/Research Support|Roche/Genentech: Grant/Research Support|The Medicine Company: Grant/Research Support Delma Nieves, MD, Merck: Grant/Research Support|Summit Therapeutics: Grant/Research Support Negar Ashouri, MD, Merck: Grant/Research Support
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
